ReviewFrontiers in pharmacology2021
Possible Benefits of
Review in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 90 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
90 citing papers in PubMed, 2 syntheses or guidelines pooled it, 141 citations in OpenAlex.
- Effect of probiotics at different intervention time on glycemic control in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.Frontiers in endocrinology · 2024Pooled it
- Identification of robust and generalizable biomarkers for microbiome-based stratification in lifestyle interventions.Microbiome · 2023Pooled it
- Gut microbial diversity at baseline conditions the clinical, microbiome, and metabolic response to paraprobioticGut microbes · 2026Trial
- Nutraceutical Blends Promote Weight Loss, Inflammation Reduction, and Better Sleep: The Role of Faecalibacterium prausnitzii in Overweight Adults-A Double-Blind Trial.Molecular nutrition & food research · 2025Trial
- Gut Microbiota Shifts After a Weight Loss Program in Adults with Obesity: The WLM3P Study.Nutrients · 2025Trial
- Impact of dietary interventions on pre-diabetic oral and gut microbiome, metabolites and cytokines.Nature communications · 2023Trial
- Risk factor obesity: treatment standard.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2026Review
- Microbiome and pancreatic ductal adenocarcinoma: mechanistic insights, microenvironmental interactions, and therapeutic implications.Molecular biology reports · 2026Review
- Impact of laparoscopic sleeve gastrectomy on gut and oral microbiota diversity, weight loss, and the metabolic outcomes.Surgery today · 2026Article
- Network topology of the gut microbiome associates with metabolic health in obesity.Nature communications · 2026Article
- Microbiome modulating remedies for chronic diseases: a review of current interventions and future directions.Inflammopharmacology · 2026Review
- Nutritional Status in Obesity: A Comprehensive Narrative Review of Dysbiosis, Micronutrient Deficiencies and the Effects of Probiotics/Synbiotics.Medicina (Kaunas, Lithuania) · 2026Review
- Exploring the gut microbiota alterations with obesity in older adults: a case-control study in the context of Bushehr Elderly Health (BEH) program.Journal of health, population, and nutrition · 2026Article
- A modified targeted culturing approach provided a snapshot into interdependencies and resistome among core anaerobic bacteria of the healthy human gut.Microbiology spectrum · 2026Article
- Probiotic and Bioactive Compounds in Foods: From Antioxidant Properties to Gut Microbiota Modulation.Molecules (Basel, Switzerland) · 2026Review
- Gut microbiota in type 2 diabetes mellitus: mechanistic links between dysbiosis, insulin resistance, and chronic low-grade inflammation.Frontiers in endocrinology · 2026Review
- The Microbial Anti-Inflammatory Molecule (MAM) is a key protein processed and exported toGut microbes · 2025Article
- Bioactive Plasmid- and Phage-Encoded Antimicrobial Peptides (AMPs) in the Human Gut: A Metatranscriptome-Virome Profiling Reveals Exploratory Links to Metabolic Human Diseases.Microbial ecology · 2025Article
- MicroSTNet: a spatio-temporal graph-based framework for time-series microbiome analysis.Microbial genomics · 2025Article
- Distinct Breast Tissue Microbiota Profiles in Early-Stage Breast Cancer: A Prospective Study in Turkish Women.Life (Basel, Switzerland) · 2025Article
30 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic disorders are an increasing concern in the industrialized world. Current research has shown a direct link between the composition of the gut microbiota and the pathogenesis of obesity and diabetes. In only a few weeks, an obesity-inducing diet can lead to increased gut permeability and microbial dysbiosis, which contributes to chronic inflammation in the gut and adipose tissues, and to the development of insulin resistance. In this review, we examine the interplay between gut inflammation, insulin resistance, and the gut microbiota, and discuss how some probiotic species can be used to modulate gut homeostasis. We focus primarily on
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.